AUSTIN, Texas, July 22, 2013 /PRNewswire/ -- Luminex Corporation (NASDAQ: LMNX) today announced it has passed a major milestone by shipping its 10,000th multiplexing instrument. This milestone was achieved by shipping a MAGPIX® instrument to Dr. Kimberle Chapin at the Rhode Island Hospital in Providence, R.I., the largest hospital and only Level I trauma center in the state. This MAGPIX instrument will be used initially for assay validation of Luminex's xTAG® Gastrointestinal Pathogen Panel.
"Shipping our 10,000th instrument is an achievement that every Luminex employee is very proud of," said Patrick J. Balthrop, president and chief executive officer of Luminex. "The substantial installed base of Luminex instruments is a testament to the flexibility of our xMAP® Technology and to the open architecture upon which our customers and partners can build their assays. It is gratifying to know that our 10,000th instrument will be used by Dr. Kimberle Chapin and her excellent team. The ability to streamline gastroenteritis testing and deliver comprehensive, timely results is important to laboratories across the country."
Since shipping its first Luminex® 100™ multiplexing instrument, Luminex has continued to drive innovation in multiplexing products and services to the global healthcare and life science research communities. Luminex is known for developing many first-to-market molecular assays, such as the first multiplex cystic fibrosis assay, the first respiratory viral panel and most recently the first gastrointestinal pathogen panel. Luminex's portfolio of multiplexing instruments and assays addresses a broad range of laboratory and budgetary needs for life science research, clinical diagnostics, and biosurveillance. The instrument line includes the 100-plex Luminex 100/200, the economical 50-plex MAGPIX and the high-throughput, 500-plex FLEXMAP 3D® systems.
Rhode Island Hospital is the principal teaching hospital of The Warren Alpert Medical School of Brown University.
About Luminex Corporation
Luminex is committed to applying its passion for innovation toward advancing healthcare and research worldwide. The Company is transforming global healthcare and life-science research through the development, manufacturing and marketing of proprietary instruments and assays utilizing xMAP open-architecture, multi-analyte platform and MultiCode® real-time polymerase chain reaction (PCR) and multiplex PCR-based technologies, that deliver cost-effective and rapid results to clinicians and researchers. Luminex's technology is commercially available worldwide and in use in leading clinical laboratories as well as major pharmaceutical, diagnostic, biotechnology and life-science companies. The Company is meeting the needs of customers in markets as diverse as clinical diagnostics, pharmaceutical drug discovery, biomedical research including genomic and proteomic research, personalized medicine, bio-defense research and food safety. For further information on Luminex Corporation and the latest advances in multiplexing using award winning technology, please visit http://www.luminexcorp.com/.
Luminex Investor Contact: Matthew Scalo, 512.219.8020 Sr. Director Investor Relations firstname.lastname@example.org
Luminex Media Contact: Mimi Torrington, 512.219.8020 Director of Marketing Communications email@example.com
SOURCE Luminex Corporation